Nathan Berger, MD is the the Hanna-Payne Professor of Experimental Medicine at Case Western Reserve University School of Medicine. They were the co-leaders of the study, called GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity, published in JAMA Oncology.
The new weight loss drugs are called glucagon-like peptide-1 receptor agonists (GLP-1RA). The first drug, exenatide (Byetta), was approved to treat type 2 diabetes (T2D)...
